Evidence map›Paper›PMID 17562051›Full record

ReviewWorld journal of urology2007

Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.

Eric C Nelson, Christopher P Evans, Chong-Xian Pan, Primo N Lara

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Eric C NelsonDepartment of Urology, University of California, Davis Medical Center, 4860 Y St, Suite 3500, Sacramento, CA 95817, USA. enelson06m@gmail.com
Christopher P Evans
Chong-Xian Pan
Primo N Lara
University of California, Davis · USUniversity of California Davis Medical Center · US

Funding

Biochemical markers of bone turnover in metastatic prostate cancerR01CA120469 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LARA, PRIMO N. · 2006 to 2010
$1.0M
NCI NIH HHS N01 CM17101NCI NIH HHS R01-CA120469
6 · The paper itself

Abstract

Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

Indexed as

Bone NeoplasmsProstatic NeoplasmsBiomarkers, TumorDiagnosis, DifferentialHumansMalePrognosisBiomarkers, Tumor

Identifiers

PMID17562051
OpenAlexW2088741852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.